Unaltered drug metabolizing enzyme systems in type II diabetes mellitus before and during glyburide therapy

Journal of Clinical Pharmacology
D JuanE J Antal

Abstract

Diabetes mellitus is associated with alterations in hepatic drug metabolizing enzyme activities in experimental animals. To determine whether Type II diabetes or glyburide affect hepatic drug metabolism, the authors used 13C-labeled aminopyrine and caffeine breath tests as in vivo probes of the hepatic cytochrome P450 and P(1)450 enzyme activities respectively in six subjects with Type II diabetes (4 women, 2 men). These subjects had been treated previously with diet, had an age range of 41-63 years, had a body mass index range of 24.1-43.3 kg/m2 and had a mean fasting plasma glucose of 14.6 +/- 1.2 mM and a mean hemoglobin A1c of 12.2 +/- 0.7%. These subjects did not drink alcohol or take drugs known to affect hepatic drug metabolism. The caffeine and aminopyrine breath tests (CBT, ABT) were performed sequentially while fasting before the start of glyburide treatment (5 mg daily) and at weekly intervals for 4 weeks. ABT and CBT values are expressed as cumulative percentage of dose exhaled through 2 hours. Before beginning glyburide, the mean ABT and CBT results were 10.2 +/- 0.7% and 4.2 +/- 0.7% respectively, well within the normal ranges for these tests (ABT 6.5-15%; CBT 2.5-10%). The ABT and CBT values remained unaltered du...Continue Reading

References

Sep 1, 1979·Clinical Pharmacology and Therapeutics·E S Vesell
Mar 1, 1978·Clinica Chimica Acta; International Journal of Clinical Chemistry·J F SchneiderP Klein
Jan 1, 1986·Developmental Pharmacology and Therapeutics·G H LambertD Hay
Aug 1, 1986·Clinical Pharmacology and Therapeutics·D JuanM C Frederiksen
Nov 1, 1983·Seminars in Liver Disease·A L BakerD A Schoeller
Jun 1, 1982·Nutrition Reviews·K E AndersonA Kappas
Feb 1, 1981·The American Journal of Medicine·T G Skillman, J M Feldman
Aug 1, 1982·Clinical Pharmacology and Therapeutics·A N KotakeH Josephs

❮ Previous
Next ❯

Citations

Nov 28, 2002·Alimentary Pharmacology & Therapeutics·A ArmuzziA Gasbarrini
Jul 7, 2007·Critical Reviews in Toxicology·T WangH M Mehendale
Jun 7, 2012·Clinical Pharmacokinetics·Miroslav DostalekMartina Puzanovova

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.